Merck is acquiring an antibiotic developer and manufacturer Cubist for $9.5 bln
Merck is acquiring an antibiotic developer and manufacturer Cubist for $9.5 bln. Cubist’s Cubicin (daptomycin) global sales exceeded $1 bln. in 2013. Cubicin is marketed by Novartis in Russia. Earlier this year FDA approved Sivextro (tedizolid phosphate), another antibiotic from Cubist. The sales of Sivextro oral form alone should reach $231 mln. by 2020. Yet another antibiotic for Cubist, ceftolozane/tazobactam, may be receiving FDA’s approval this month. Cubist’s target portfolio sales should amount to $1.3 bln. in 2015 according to EvaluatePharma®.
Sources: Pharmvestnik, EvaluatePharma®, cubist.com, EP Vantage